Trial Profile
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Selumetinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Jul 2023 Planned End Date changed from 30 Jun 2025 to 30 Jun 2026.
- 17 Jul 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 01 Aug 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Jun 2023.